NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Atezolizumab for treating non-small-cell lung cancer after platinum-based chemotherapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equality issues were identified during scoping.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No equality issues were raised.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No equality issues were identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Technology appraisals: Guidance development

No.	
5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.	
6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A	
7.	Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Approved by Associate Director (name):Frances Sutcliffe...

Date: 26 June 2017

2nd consultation

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No equality issues have been raised this is noted in section 3.18 in the ACD.

No equality issues were raised.

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of atezolizumab for treating non-small-cell lung cancer after platinum-based

Issue date: May 2018

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No changes to the recommendations.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No changes to the recommendations.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No changes to the recommendations.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No equality issues were raised.

Approved by Associate Director (name):Frances Sutcliffe......

Date: 04/10/2017

chemotherapy Issue date: May 2018

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No equality issues were raised.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

No equality issues were raised.

Approved by Associate Director (name):Frances Sutcliffe......

Date: 12/03/2018

chemotherapy 5 of 5 Issue date: May 2018